YIYusuke Iizawa

Yusuke Iizawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yusuke Iizawa has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preoperative Risk Classification for Early Recurrence After Curative-Intent Resection of Perihilar Cholangiocarcinoma: A Single-Center Retrospective Study

    by Yu Fujimura, Naohisa Kuriyama, Yuki Segi, Haruna Komatsubara, Kazuyuki Gyoten, Takahiro Ito, Aoi Hayasaki, Takehiro Fujii, Yusuke Iizawa, Yasuhiro Murata, et al.

    Background/Objectives: Early recurrence (ER) after curative-intent resection of perihilar cholangiocarcinoma (PHC) is associated with poor prognosis. However, simple preoperative predictors remain insufficiently defined. This study aimed to identify preoperative factors associated with ER and explore a risk classification. Methods: We retrospectively analyzed 108 patients who underwent curative-intent resection for PHC at a single institution between 2007 and 2023. ER was defined as recurrence within 1 year after surgery. Cox proportional hazards regression was used to identify associated factors. Results: ER occurred in 24 patients (22.2%). Multivariable analysis identified younger age (hazard ratio [HR] = 0.942), higher carcinoembryonic antigen (CEA; HR = 1.115), higher carbohydrate antigen 19-9 (CA19-9; HR = 1.001), and higher neutrophil-to-lymphocyte ratio (NLR; HR = 1.404) as factors associated with ER. In an exploratory classification, one point was assigned for age < 61 years, CEA ≥ 5.4 ng/mL, CA19-9 ≥ 89.4 U/mL, and NLR ≥ 2.037. Among 105 patients with complete data, the estimated 1-year recurrence rate was 70.0% in patients with 3–4 points (n = 10), versus 17.4% in those with 0–2 points (n = 95; p < 0.001). Bootstrap analysis suggested optimism in the score’s apparent discrimination when cutoff optimization was considered (optimism-corrected C-index, 0.668). Conclusions: Age, CEA, CA19-9, and NLR were associated with ER after PHC resection. The exploratory classification requires external validation before clinical use.

  • Open Access

    Long-Term Outcomes of Anatomical and Biological Borderline Resectable Pancreatic Ductal Adenocarcinoma After Gemcitabine/S-1-Based Neoadjuvant Chemoradiotherapy

    by Haruna Komatsubara, Shugo Mizuno, Daisuke Noguchi, Naohisa Kuriyama, Aoi Hayasaki, Yuki Segi, Kazuyuki Gyoten, Takahiro Ito, Yusuke Iizawa, Takehiro Fujii, et al.

    Background/Objectives: Oncological outcomes in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) remain unclear. This long-term observational study evaluated these outcomes in patients with BR-PDAC treated with a consistent neoadjuvant chemoradiotherapy (CRT) regimen and explored host-related prognostic markers. Methods: We retrospectively analyzed 206 patients with PDAC who received neoadjuvant gemcitabine plus S-1 with concurrent radiotherapy between 2011 and 2022. Biological BR was defined as anatomically resectable disease with an initial carbohydrate antigen 19-9 (CA19-9) level ≥500 U/mL. Anatomical BR was subdivided into portal venous involvement (BR-PV) and arterial involvement (BR-A). Outcomes were compared according to resectability and surgical resection, with resectable (R) patients as a reference. Prognostic factors among resected BR patients were assessed using multivariable Cox regression analysis. Results: The median follow-up was 62.5 months. Resection rates were 85.7%, 83.3%, 69.8%, and 55.6% for R, biological BR, BR-PV, and BR-A, respectively. Although the resection rate of biological BR was similar to that of R, its survival did not differ significantly from that of anatomical BR. Across all BR subtypes, surgical resection was associated with longer overall survival. Among resected patients, the post-CRT neutrophil-lymphocyte-to-monocyte ratio (NL/M), a peripheral blood cell index, was associated with overall survival (hazard ratio 1.020, p = 0.009). Patients with a high post-CRT NL/M had poorer prognosis than those with a low NL/M (p = 0.001). Conclusions: Biological and anatomical BR-PDAC showed no significant difference in long-term survival after neoadjuvant CRT, and surgical resection was associated with longer survival across BR subtypes. Post-CRT NL/M was associated with overall survival after resection and may serve as a potential host-related prognostic marker, although further validation is needed.

  • Open Access

    Long-Term Outcomes of a Multidisciplinary Treatment Strategy Using Neoadjuvant Gemcitabine Plus S-1 Based on Anatomical Resectability Classification and Lymph Node Status in Patients with Perihilar Cholangiocarcinoma

    by Naohisa Kuriyama, Shugo Mizuno, Yuki Segi, Haruna Komatusbara, Kazuyuki Gyoten, Takahiro Ito, Aoi Hayasaki, Takehiro Fujii, Yusuke Iizawa, Yasuhiro Murata, et al.

    Objectives: The long-term impact of neoadjuvant chemotherapy (NAC) based on anatomical resectability for perihilar cholangiocarcinoma (PHC) remains unclear. We evaluated the mature long-term outcomes of our multidisciplinary treatment strategy based on anatomical resectability classification and regional lymph node (LN) status using gemcitabine plus S-1 (NAC-GS). Methods: Between September 2010 and August 2021, 110 consecutive PHC patients were classified as resectable (R; n = 47), borderline resectable (BR; n = 38), or unresectable locally advanced (UR-LA; n = 25) according to our anatomical resectability classification. NAC-GS was administered to patients with clinically positive LN metastasis and to BR and UR-LA patients. Long-term overall survival (OS), recurrence-free survival (RFS), and prognostic factors were evaluated. Results: NAC-GS was administered to 72 patients (65.5%). Curative-intent resection was achieved in 40 (85.1%), 25 (65.8%), and 6 (24.0%) patients in the R, BR, and UR-LA groups, respectively. In the overall cohort, anatomical resectability significantly stratified OS (p = 0.032). However, among patients who underwent curative-intent resection, OS and RFS were comparable across the three resectability groups. Those receiving NAC-GS showed favorable long-term survival despite having more advanced disease characteristics; however, this comparison was limited to selected patients who ultimately proceeded to surgery. Multivariable analysis identified preoperative serum carcinoembryonic antigen ≥5.5 ng/mL (HR: 3.174, p = 0.003), non-adjuvant therapy (HR: 2.222, p = 0.023) and pathological T4 (HR: 2.397, p = 0.037) as independent predictors of poor survival. Conclusions: Anatomical resectability was associated with long-term prognosis and the likelihood of achieving curative-intent resection. Selected patients who ultimately underwent curative-intent resection after NAC-GS showed favorable long-term outcomes; however, these findings do not establish a survival benefit of NAC-GS over upfront surgery. Prospective multi-institutional validation is warranted.

  • Open Access

    Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy

    by Aoi Hayasaki, Shugo Mizuno, Benson Kaluba, Yuki Segi, Haruna Komatsubara, Tatsuya Sakamoto, Koki Maeda, Toru Shinkai, Takahiro Ito, Kazuyuki Gyoten, et al.


  • Open Access

    Prognostic impacts of biological and conditional factors in patients with anatomically resectable pancreatic adenocarcinoma treated with preoperative chemoradiotherapy

    by Yasuhiro Murata, Shugo Mizuno, Masashi Kishiwada, Aoi Hayasaki, Motonori Nagata, Daisuke Noguchi, Kazuyuki Gyoten, Takahiro Ito, Takehiro Fujii, Yusuke Iizawa, et al.

    The efficacy of preoperative chemoradiotherapy (CRT) for anatomically resectable pancreatic adenocarcinoma (R-PDAC) remains contentious. This study aims to elucidate the treatment outcomes of preoperative CRT for R-PDAC and to identify prognostic factors. This retrospective study included 109 R-PDAC patients treated with gemcitabine- or S-1 plus gemcitabine-based preoperative CRT from February 2005 to April 2023. Cox proportional hazards regression was employed to identify factors associated with worse overall survival (OS). Among the 109 cases, 90 patients (82.6%) underwent curative-intent resection following CRT. The median OS for the entire cohort was 36.5 months, significantly longer in resected cases than in unresected cases (40.6 vs 11.4 months). Multivariate analysis identified pretreatment serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) and the Eastern Cooperative Oncology Group performance status ≥1 as independent prognostic factors. When these factors were scored (risk score 0–3) using pre-CRT serum CA19-9 level (≥640 U/mL) and CEA (≥6.1 ng/mL), OS for risk scores 1 (n = 41), 2 (n = 20) or 3 (n = 6) was significantly shorter than for risk score 0 (n = 42) (score 0 vs 1 vs 2 vs 3: 49.1 vs 33.8 vs 16.1 vs 16.8 months). The presence of portal vein invasion on imaging and post-CRT serum CA 19-9 level (≥111 U/mL) were independent prognostic factors in resected cases. Biological factors, including serum levels of CA19-9 and CEA, along with conditional factor of Eastern Cooperative Oncology Group performance status ≥1, were identified as independent prognostic factors for R-PDAC patients treated with preoperative CRT. Preoperative CRT is considered effective for cases lacking these risk factors.


  • Open Access

    Impact of Surgical Resection After Induction Gemcitabine Plus S-1-Based Chemoradiotherapy in Patients with Locally Advanced Pancreatic Ductal Adenocarcinoma: A Focus on UR-LA Cases

    by Masashi Kishiwada, Shugo Mizuno, Aoi Hayasaki, Benson Kaluba, Takehiro Fujii, Daisuke Noguchi, Takahiro Ito, Yusuke Iizawa, Akihiro Tanemura, Yasuhiro Murata, et al.

    Background: This study aimed to assess the safety and efficacy of gemcitabine plus S-1-based chemoradiotherapy (GS-CRT) among patients with locally advanced pancreatic ductal adenocarcinoma (PDAC), especially among those with unresectable locally advanced (UR-LA) cases. Methods: A total of 351 consecutive PDAC patients were enrolled and prognostic predictors of disease-specific survival (DSS) were identified. Results: The treatment completion rate was 98.9% and Grade 3 or higher adverse events occurred in 181 cases (51.6%). Among 319 re-evaluated patients, pancreatectomy was performed in 184 (57.7%). Based on resectability, the 5-year DSS rates for the entire cohort were 39.6% (R), 43.8% (BR-PV), 21.2% (BR-A) and 13.3% (UR-LA), while the predictors of DSS were performance status (PS), hemoglobin (Hb) level, celiac artery (CA) involvement of ≥180 degrees and JPS 8th T category. In the resected cases, the predictors of DSS were preoperative PS, preoperative CA19-9 level, preoperative JPS-T factor, degree of histological response and adjuvant chemotherapy. In UR-LA resected patients, preoperative prognostic nutritional index (PNI), absence of pathological venous invasion and adjuvant chemotherapy were predictors of DSS. Conclusions: Even though Grade 3 or higher adverse events were encountered in about half of the cases, they were uneventfully managed. Therefore, GS-CRT is safe and highly tolerable with potential to improve patients‘ prognosis. Preoperative PS, CA19-9 levels and histological response are important prognostic factors, as well as adjuvant therapy. In UR-LA patients, prognostic nutritional index (PNI) and adjuvant chemotherapy were important for curative intent surgery.


  • Open Access

    Distinct prognostic impacts of age-adjusted Charlson comorbidity index and geriatric nutritional risk index in patients with intraductal papillary mucinous neoplasm

    by Takuya Yuge, Yasuhiro Murata, Takahiro Ito, Aoi Hayasaki, Yusuke Iizawa, Takehiro Fujii, Akihiro Tanemura, Naohisa Kuriyama, Masashi Kishiwada, Shugo Mizuno

    The optimal surgical indication for intraductal papillary mucinous neoplasms (IPMN) remains highly contentious. We aimed to determine the preoperative predictive factors of malignancy and independent prognostic factors in patients with IPMN who underwent curative-intent resection. In this study, 104 patients with a pathological diagnosis of IPMN who underwent curative-intent resection were included. Multivariate regression and Cox proportional-hazards analyses were performed to identify the predictive factors for invasive intraductal papillary mucinous carcinoma (IPMC) and prognostic factors for overall survival (OS) after surgery. Among the 104 patients, 24 (23.1%) were pathologically diagnosed with invasive IPMC, and the remaining 80 had low-grade dysplasia or high-grade dysplasia. The presence of high-risk stigmata was an independent predictive risk factor for invasive IPMC. The age-adjusted Charlson comorbidity index (ACCI) (≥4/P = .006 and HR: 4.37; 95% CI: 1.07–17.86, P = .040, respectively). Forty patients with ACCI ≥ 4 (38.5%) had a significantly lower 5-year OS rate than those with ACCI < 4 (74.3 vs 98.2%, P < .001). Similarly, 29 patients with GNRI < 99 (27.9%) had a significantly lower 5-year OS rate than those with GNRI ≥ 99 (76.0 vs 95.1%, P < .001). These 2 factors were associated with significantly worse disease-specific survival after surgery. The ACCI and GNRI emerged as independent prognostic factors after surgery in patients with IPMN. These findings highlight the importance of patient-conditional factors as valuable indicators for predicting favorable long-term survival outcomes after surgery and for facilitating a more precise assessment of surgical eligibility in patients with IPMN.


  • Surgical outcomes of the Frey procedure for chronic pancreatitis: correlation between preoperative characteristics and the histological severity of pancreatic fibrosis

    by Akihiro Tanemura, Akinobu Hayashi, Koki Maeda, Toru Shinkai, Takahiro Ito, Aoi Hayasaki, Kazuyuki Gyoten, Takehiro Fujii, Yusuke Iizawa, Yasuhiro Murata, et al.

    Purpose To evaluate the efficacy of the Frey procedure and clarify the relationship between preoperative characteristics and the histological severity of chronic pancreatitis (CP). Methods Thirty patients who underwent the Frey procedure for CP between January, 2002 and December, 2020, at our hospital, were enrolled in this study. The specimen cored out of the pancreatic head was assessed for CP severity. We evaluated preoperative status and surgical outcomes according to CP severity. Results Long-term pain relief was achieved in all 26 patients with sustained long-term follow-up, with complete pain relief attained in 19 (63%). Albumin levels were significantly higher 1 year postoperatively than preoperatively (p = 0.038). Histological fibrosis was assessed in the 26 patients as follows: normal (n = 4; 15%), mild (n = 8; 31%), moderate (n = 2; 8%), and severe (n = 12; 46%). These patients were divided into two groups according to the severity of fibrosis: normal/mild (n = 12) and moderate/severe (n = 14). The rates of diffuse calcification on preoperative computed tomography (CT) (71% vs. 17%, p = 0.008) and islet atrophy on insulin immunohistochemistry (100% vs. 33%, p < 0.001) were significantly higher in the moderate/severe group than in the normal/mild group. Conclusion The Frey procedure can achieve good pain relief and improve nutritional status. The severity of fibrosis can be predicted based on the extent of calcification on preoperative imaging studies.